X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs TEVA PHARMA (Israel) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   TEVA PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
TEVA PHARMA
Dec-13
LUPIN LTD/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7502,709-   
Low Rs1,3842,353-   
Sales per share (Unadj.) Rs387.41,554.5-  
Earnings per share (Unadj.) Rs56.697.1-  
Cash flow per share (Unadj.) Rs76.8222.8-  
Dividends per share (Unadj.) Rs7.5085.01-  
Dividend yield (eoy) %0.53.4 14.3%  
Book value per share (Unadj.) Rs298.91,726.7-  
Shares outstanding (eoy) m451.58848.00-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.01.6 248.4%   
Avg P/E ratio x27.726.1 106.2%  
P/CF ratio (eoy) x20.411.4 179.5%  
Price / Book Value ratio x5.21.5 357.6%  
Dividend payout %13.287.5 15.1%   
Avg Mkt Cap Rs m707,5132,146,042 33.0%   
No. of employees `00016.844.9 37.4%   
Total wages/salary Rs m28,4950-   
Avg. sales/employee Rs Th10,418.329,328.6 35.5%   
Avg. wages/employee Rs Th1,697.00-   
Avg. net profit/employee Rs Th1,523.01,832.1 83.1%   
INCOME DATA
Net Sales Rs m174,9431,318,175 13.3%  
Other income Rs m1,0650-   
Total revenues Rs m176,0081,318,175 13.4%   
Gross profit Rs m44,931360,983 12.4%  
Depreciation Rs m9,122106,549 8.6%   
Interest Rs m1,52525,891 5.9%   
Profit before tax Rs m35,349228,543 15.5%   
Minority Interest Rs m-721,038 -6.9%   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m9,785-2,790 -350.7%   
Profit after tax Rs m25,57582,345 31.1%  
Gross profit margin %25.727.4 93.8%  
Effective tax rate %27.7-1.2 -2,267.3%   
Net profit margin %14.66.2 234.0%  
BALANCE SHEET DATA
Current assets Rs m119,542890,291 13.4%   
Current liabilities Rs m61,206776,409 7.9%   
Net working cap to sales %33.38.6 386.0%  
Current ratio x2.01.1 170.3%  
Inventory Days Days7691 83.7%  
Debtors Days Days9096 93.7%  
Net fixed assets Rs m131,660430,545 30.6%   
Share capital Rs m9033,245 27.8%   
"Free" reserves Rs m134,0730-   
Net worth Rs m134,9761,464,243 9.2%   
Long term debt Rs m56,478674,012 8.4%   
Total assets Rs m266,0733,012,453 8.8%  
Interest coverage x24.29.8 246.0%   
Debt to equity ratio x0.40.5 90.9%  
Sales to assets ratio x0.70.4 150.3%   
Return on assets %10.23.6 283.5%  
Return on equity %18.95.6 336.9%  
Return on capital %19.34.9 390.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m60,3780-   
CASH FLOW
From Operations Rs m41,148210,049 19.6%  
From Investments Rs m-25,287-74,429 34.0%  
From Financial Activity Rs m4,332-251,968 -1.7%  
Net Cashflow Rs m20,193-116,348 -17.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare LUPIN LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare LUPIN LTD With: DIVIS LABORATORIES  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS